MiR-16 attenuates &bgr;-amyloid-induced neurotoxicity through targeting &bgr;-site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer’s disease cell model

The aberrant deposition of &bgr;-amyloid (A&bgr;) is closely linked to the pathogenesis and development of Alzheimer’s disease (AD). MiR-16 was abnormally downregulated and may be related to the development of AD. However, the functional role and molecular mechanism of miR-16 in AD pathogenesis are still not well elucidated. The expressions of miR-16 and &bgr;-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA and protein levels in AD brain tissues and A&bgr;-treated PC12 cellular AD model were examined by qRT-PCR and western blot analyses. Luciferase reporter assay was used to verify the potential target of miR-16. The cell viability, apoptosis, and caspase-3 activity in PC12 cells were determined by the MTT assay, flow cytometry analysis, and caspase-3 activity assay, respectively. Downregulation of miR-16 and upregulation of BACE1 existed in AD tissues and the cellular AD model of PC12. In addition, miR-16 directly suppressed BACE1 expression. Moreover, miR-16 overexpression and BACE1 knockdown facilitated A&bgr;-induced cell toxicity, apoptosis, and caspase-3 activity in N2a cells, which was partially eliminated by overexpression of BACE1. In contrast, BACE1 knockdown reversed the miR-16 inhibition-mediated inhibitory effect on A&bgr;-induced cell toxicity, apoptosis, and caspase-3 activity in PC12 cells. Collectively, miR-16 attenuated A&bgr;-induced neurotoxicity through targeting BACE1 in an A&bgr; insult cellular AD model, providing a potential therapeutic target for AD treatment.

[1]  J. Teng,et al.  MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1 , 2012, Brain Research Bulletin.

[2]  Peter T. Nelson,et al.  Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter , 2011, Acta Neuropathologica.

[3]  R. Berry,et al.  β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis , 2007, The Journal of Neuroscience.

[4]  K. Blennow,et al.  O3-02-06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease , 2008, Alzheimer's & Dementia.

[5]  Wenjin Xi,et al.  MiR‐200c suppresses TGF‐β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer , 2014, International journal of cancer.

[6]  M. Fang,et al.  miR-124 downregulates BACE 1 and alters autophagy in APP/PS1 transgenic mice. , 2017, Toxicology letters.

[7]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[8]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[9]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[10]  Qunfeng Lin,et al.  MiR-16 regulates cell death in Alzheimer's disease by targeting amyloid precursor protein. , 2015, European review for medical and pharmacological sciences.

[11]  Aikaterini S. Papadopoulou,et al.  Alteration of the microRNA network during the progression of Alzheimer's disease , 2013, EMBO molecular medicine.

[12]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[13]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[14]  Pei-Chang Wang,et al.  MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease. , 2014, International journal of molecular medicine.

[15]  C. Moussa.  Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease , 2017, Expert opinion on investigational drugs.

[16]  L. Hritcu,et al.  Cognitive-enhancing activities of the polyprenol preparation Ropren® in gonadectomized β-amyloid (25–35) rat model of Alzheimer's disease , 2016, Physiology & Behavior.

[17]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[18]  Sarah Crunkhorn.  BACE1 inhibitor reduces β-amyloid production in humans , 2016, Nature reviews. Drug discovery.

[19]  S. Hébert,et al.  Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease , 2015, Molecular therapy. Nucleic acids.

[20]  X. Zhang,et al.  Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas , 2012, Oncogene.

[21]  Yan Cheng,et al.  miR-16-1 Promotes the Aberrant α-Synuclein Accumulation in Parkinson Disease via Targeting Heat Shock Protein 70 , 2014, TheScientificWorldJournal.

[22]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[23]  B. Strooper,et al.  BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease , 2016, Trends in Neurosciences.

[24]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[25]  H. Cai,et al.  BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. , 2001, Nature neuroscience.

[26]  Wenjin Xi,et al.  MiR-200 c suppresses TGF-b signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF 217 and ZEB 1 in breast cancer , 2014 .

[27]  R. Yan,et al.  Neurological dysfunctions associated with altered BACE1‐dependent Neuregulin‐1 signaling , 2016, Journal of neurochemistry.

[28]  Y. Fujiki,et al.  Reduction of Ether-Type Glycerophospholipids, Plasmalogens, by NF-κB Signal Leading to Microglial Activation , 2017, The Journal of Neuroscience.

[29]  N. Rezaei,et al.  MicroRNA in Alzheimer’s disease revisited: implications for major neuropathological mechanisms , 2018, Reviews in the neurosciences.

[30]  Anna M. Krichevsky,et al.  MiR-26b, Upregulated in Alzheimer's Disease, Activates Cell Cycle Entry, Tau-Phosphorylation, and Apoptosis in Postmitotic Neurons , 2013, The Journal of Neuroscience.

[31]  Cheng-xi Wei,et al.  miR-15b represses BACE1 expression in sporadic Alzheimer’s disease , 2017, Oncotarget.

[32]  L. Buée,et al.  MicroRNAs and the Regulation of Tau Metabolism , 2012, International journal of Alzheimer's disease.

[33]  B. Austen,et al.  Protein–protein interactions in the assembly and subcellular trafficking of the BACE (β-site amyloid precursor protein-cleaving enzyme) complex of Alzheimer's disease , 2007 .

[34]  H. Hampel,et al.  Beta‐site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease , 2009, Scandinavian journal of clinical and laboratory investigation.

[35]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[36]  Xiaozhong Peng,et al.  MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice , 2012, Neurobiology of Aging.